相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dupilumab zur Behandlung von Genodermatosen: Eine systematische Übersicht
Po‐Chien Wu et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)
Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa
Vladislav Oldakovskiy et al.
JOURNAL OF PEDIATRIC SURGERY (2023)
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study
Johannes S. Kern et al.
BRITISH JOURNAL OF DERMATOLOGY (2023)
Interleukin-17A immune pattern across genetic acantholytic and blistering disorders
Asal Haghighi Javid et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2023)
Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab
Ling Yu et al.
Dermatitis (2023)
Control del prurito refractario en epidermólisis ampollosa pruriginosa con dupilumab
B. Roque Quintana et al.
Actas Dermo-Sifiliograficas (2023)
COL7A1 Editing via RNA Trans-Splicing in RDEB-Derived Skin Equivalents
Bernadette Liemberger et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database
Gabriela Petrof et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Successful use of tofacitinib in epidermolysis bullosa pruriginosa
K. -J. Chen et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)
Transcriptomic profiling of recessive dystrophic epidermolysis bullosa wounded skin highlights drug repurposing opportunities to improve wound healing
Alexandros Onoufriadis et al.
EXPERIMENTAL DERMATOLOGY (2022)
5′RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa
Elisabeth Mayr et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab
F. Caroppo et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
The clinical efficacy and safety of anti-IgE therapy in recessive dystrophic epidermolysis bullosa
Fuying Chen et al.
CLINICAL GENETICS (2022)
Losartan treatment improves recessive dystrophic epidermolysis bullosa: A case series
Mohammad Reza Pourani et al.
DERMATOLOGIC THERAPY (2022)
Dystrophic epidermolysis bullosa pruriginosa: a new case series of a rare phenotype unveils skewed Th2 immunity
D. Darbord et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial
Irina Gurevich et al.
NATURE MEDICINE (2022)
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants
Daniel Mosallaei et al.
JAMA DERMATOLOGY (2022)
Evaluation of Systemic Gentamicin as Translational Readthrough Therapy for a Patient With Epidermolysis Bullosa Simplex With Muscular Dystrophy Owing to PLEC1 Pathogenic Nonsense Variants
Lucia Martinez-Santamaria et al.
JAMA DERMATOLOGY (2022)
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
Shireen V. V. Guide et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The C4EB study-Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
Nicholas H. B. Schraeder et al.
PLOS ONE (2022)
Losartan as therapy for recessive dystrophic epidermolysis bullosa: Report of three cases
Maria Relvas et al.
DERMATOLOGIC THERAPY (2022)
ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation
Adam Sheriff et al.
SCIENTIFIC REPORTS (2022)
295 Collagen 7 (C7) protein replacement therapy (PTR-01) durably reduces wound size and symptoms in patients with recessive dystrophic epidermolysis bullosa (RDEB)
A. Bruckner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)
Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa
Sung-Ah Hong et al.
MOLECULAR THERAPY (2022)
Mesenchymal Stem Cell-Derived Extracellular Vesicles as an Advanced Therapy for Chronic Wounds
Eric R. Bray et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2022)
Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa
James A. Feinstein et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study
A. Angelis et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
Jodi Y. So et al.
ORPHANET JOURNAL OF RARE DISEASES (2022)
Improved erythema and decreased blister formation in dominant dystrophic epidermolysis bullosa following treatment with pulsed dye laser
Anna Cristina Garza-Mayers et al.
PEDIATRIC DERMATOLOGY (2022)
The C4EB study-Transvamix (10% THC/5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
Nicholas H. B. Schrader et al.
PLOS ONE (2022)
Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds
C. L. Ebens et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Prevalence, pathophysiology and management of itch in epidermolysis bullosa
M. Papanikolaou et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study
Olivier Bornert et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)
Epidermolysis bullosa pruriginosa treated with dupilumab
Amanda G. Zhou et al.
PEDIATRIC DERMATOLOGY (2021)
Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients
Sang Eun Lee et al.
JCI INSIGHT (2021)
Applications of Mesenchymal Stem Cells in Skin Regeneration and Rejuvenation
Hantae Jo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A case of recessive dystrophic epidermolysis bullosa treated with a cultured epidermal autograft
Ryosuke Mochizuki et al.
JOURNAL OF DERMATOLOGY (2021)
Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial
Christina Guttmann-Gruber et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study
Y. Fujita et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa
Grace Tartaglia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Antisense Oligonucleotide-Based Therapy of Viral Infections
Woan-Yuh Tarn et al.
PHARMACEUTICS (2021)
Mesenchymal stromal cells in wound healing applications: role of the secretome, targeted delivery and impact on recessive dystrophic epidermolysis bullosa treatment
Julia Riedl et al.
CYTOTHERAPY (2021)
Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report
Yangbin Wang et al.
DERMATOLOGIC THERAPY (2021)
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study
Nicholas H. B. Schrader et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Epidermolysis Bullosa Pruriginosa Treated With Baricitinib
Xingyuan Jiang et al.
JAMA DERMATOLOGY (2021)
ABCB5+dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment
Julia Riedl et al.
STEM CELLS (2021)
Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs
Mark J. Osborn et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa
Ellie Rashidghamat et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
C. Has et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab
W. Shehadeh et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
High-mobility group box 1 fragment suppresses adverse post-infarction remodeling by recruiting PDGFRα-positive bone marrow cells
Takasumi Goto et al.
PLOS ONE (2020)
Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa
Toini Pemmari et al.
MOLECULAR THERAPY (2020)
RNA delivery by extracellular vesicles in mammalian cells and its applications
Killian O'Brien et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2020)
306 Topical QR-313, an Antisense Oligonucleotide, in the Treatment of Dystrophic Epidermolysis Bullosa
M.P. Marinkovich et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Nonsequential Splicing Events Alter Antisense-Mediated Exon Skipping Outcome in COL7A1
Kristin A. Ham et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Epidermolysis bullosa
Ajoy Bardhan et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Successful use of cyclosporine in epidermolysis bullosa pruriginosa
Akanksha Kaushik et al.
DERMATOLOGIC THERAPY (2020)
Extracellular Vesicles, Apoptotic Bodies and Mitochondria: Stem Cell Bioproducts for Organ Regeneration
Natalia Gebara et al.
CURRENT TRANSPLANTATION REPORTS (2020)
Epidermolysis bullosa simplex generalized severe induces a T helper 17 response and is improved by apremilast treatment
E. Castela et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
The Wound Healing Properties of Betulin from Birch Bark from Bench to Bedside
Armin Scheffler
PLANTA MEDICA (2019)
Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa
K. Twaroski et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
1021 Intravenous gentamicin therapy for recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations
D. Woodley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Mechanism of Oleogel-S10: A triterpene preparation for the treatment of epidermolysis bullosa
Agnes Schwieger-Briel et al.
DERMATOLOGIC THERAPY (2019)
The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review
Ali Golchin et al.
CURRENT STEM CELL RESEARCH & THERAPY (2019)
Search-and-replace genome editing without double-strand breaks or donor DNA
Andrew V. Anzalone et al.
NATURE (2019)
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
N. H. B. Schrader et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Therapies for epidermolysis bullosa: delivery is key
R. F. L. O'Shaughnessy
BRITISH JOURNAL OF DERMATOLOGY (2019)
Decorin counteracts disease progression in mice with recessive dystrophic epidermolysis bullosa
Francesca Cianfarani et al.
MATRIX BIOLOGY (2019)
CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells
Joanna Jackow et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa
Su M. Lwin et al.
JCI INSIGHT (2019)
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa
Shaundra Eichstadt et al.
JCI INSIGHT (2019)
Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts
Jeffrey D. McBride et al.
BIOCHIMIE (2018)
Cultured allogeneic fibroblast injection vs. fibroblasts cultured on amniotic membrane scaffold for dystrophic epidermolysis bullosa treatment
H. Moravvej et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
A phase 1/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB)
M. Marinkovich et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
EB2017-Progress in Epidermolysis Bullosa Research toward Treatment and Cure
Jouni Uitto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Self-initiated use of topical cannabidiol oil for epidermolysis bullosa
Malcolm P. Chelliah et al.
PEDIATRIC DERMATOLOGY (2018)
Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa
Alexander Nystroem et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells
Ulf Andersson et al.
SEMINARS IN IMMUNOLOGY (2018)
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair
Araksya Izmiryan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential
Westley J. Friesen et al.
PLOS ONE (2018)
Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes
Christina Guttmann-Gruber et al.
SCIENTIFIC REPORTS (2018)
Base editing: precision chemistry on the genome and transcriptome of living cells
Holly A. Rees et al.
NATURE REVIEWS GENETICS (2018)
The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster
Takashi Kido et al.
PLOS ONE (2018)
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Clotilde Thery et al.
JOURNAL OF EXTRACELLULAR VESICLES (2018)
RNA-based therapies for genodermatoses
Olivier Bornert et al.
EXPERIMENTAL DERMATOLOGY (2017)
Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients
David T. Woodley et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Amlexanox Enhances Premature Termination Codon Read-Through in COL7A1 and Expression of Full Length Type VII Collagen: Potential Therapy for Recessive Dystrophic Epidermolysis Bullosa
Velina S. Atanasova et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells
Beau R. Webber et al.
LABORATORY INVESTIGATION (2017)
Programmable base editing of A.T to G.C in genomic DNA without DNA cleavage
Nicole M. Gaudelli et al.
NATURE (2017)
Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study
Agnes Schwieger-Briel et al.
DERMATOLOGY RESEARCH AND PRACTICE (2017)
Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial
Mohammad El-Darouti et al.
DERMATOLOGIC THERAPY (2016)
Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa
Zurab Siprashvili et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model
Sandrina Turczynski et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy
Olivier Bornert et al.
MOLECULAR THERAPY (2016)
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Alexis C. Komor et al.
NATURE (2016)
Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa
Satoru Shinkuma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
Jeroen Bremer et al.
Molecular Therapy-Nucleic Acids (2016)
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Alexander Nystroem et al.
EMBO MOLECULAR MEDICINE (2015)
Intravenously Administered Recombinant Human Type VII Collagen Derived from Chinese Hamster Ovary Cells Reverses the Disease Phenotype in Recessive Dystrophic Epidermolysis Bullosa Mice
Yingping Hou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa
Gabriela Petrof et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa
Mark B. Geyer et al.
JOURNAL OF PEDIATRICS (2015)
Mesenchymal stem cell exosomes
Ruenn Chai Lai et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
Case Report: Rapidly Healing Epidermolysis Bullosa Wound After Ablative Fractional Resurfacing
Andrew C. Krakowski et al.
PEDIATRICS (2015)
Long-term Follow-up of Cultured Epidermal Autograft in a Patient with Recessive Dystrophic Epidermolysis Bullosa
Satoru Shinkuma et al.
ACTA DERMATO-VENEREOLOGICA (2014)
Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity
Teresa Odorisio et al.
HUMAN MOLECULAR GENETICS (2014)
Aminoglycosides Restore Full-length Type VII Collagen by Overcoming Premature Termination Codons: Therapeutic Implications for Dystrophic Epidermolysis Bullosa
Jon Cogan et al.
MOLECULAR THERAPY (2014)
Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial
G. Petrof et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Intravenously Injected Recombinant Human Type VII Collagen Homes to Skin Wounds and Restores Skin Integrity of Dystrophic Epidermolysis Bullosa
David T. Woodley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa
Supriya S. Venugopal et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix
Jakub Tolar et al.
LANCET (2013)
A Reporter-Based Screen to Identify Potent 3' Trans-Splicing Molecules for Endogenous RNA Repair
Eva M. Murauer et al.
HUMAN GENE THERAPY METHODS (2013)
A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays
Stuart P. McElroy et al.
PLOS BIOLOGY (2013)
siRNA-Mediated Allele-Specific Inhibition of Mutant Type VII Collagen in Dominant Dystrophic Epidermolysis Bullosa
Valerie Pendaries et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Sense from nonsense: therapies for premature stop codon diseases
Laure Bidou et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Functional Correction of Type VII Collagen Expression in Dystrophic Epidermolysis Bullosa
Eva M. Murauer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
HB-EGF Induces COL7A1 Expression in Keratinocytes and Fibroblasts: Possible Mechanism Underlying Allogeneic Fibroblast Therapy in Recessive Dystrophic Epidermolysis Bullosa
Nikoletta Nagy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia
Katsuto Tamai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa
Paulette Conget et al.
CYTOTHERAPY (2010)
Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin Tissue
Zurab Siprashvili et al.
HUMAN GENE THERAPY (2010)
Low-level laser therapy for the treatment of epidermolysis bullosa: A case report
Eliana Maria Minicucci et al.
JOURNAL OF COSMETIC AND LASER THERAPY (2010)
Revertant Mosaicism in Recessive Dystrophic Epidermolysis Bullosa
Noor Almaani et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
SIN Retroviral Vectors Expressing COL7A1 Under Human Promoters for Ex Vivo Gene Therapy of Recessive Dystrophic Epidermolysis Bullosa
Matthias Titeux et al.
MOLECULAR THERAPY (2010)
Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa
John E. Wagner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells
Jakub Tolar et al.
BLOOD (2009)
Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006
Jo-David Fine et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance
Takenao Chino et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa
Tracy Wong et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Targeted skipping of a single exon harboring a premature termination codon mutation: Implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients
Maki Goto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa
Maki Goto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa
DT Woodley et al.
NATURE MEDICINE (2004)
Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors
C Baldeschi et al.
HUMAN MOLECULAR GENETICS (2003)
Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation
H Takahashi et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2003)
Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue
S Ortiz-Urda et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone
DT Woodley et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa
M Chen et al.
NATURE GENETICS (2002)
Development and characterization of a recombinant truncated type VII collagen minigene - Implication for gene therapy of dystrophic epidermolysis bullosa
M Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)